文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

二叶式主动脉瓣狭窄患者经导管主动脉瓣植入术后升主动脉持续扩张的发生率及预测因素

Incidence and predictors of continued ascending aortic dilatation after TAVI in patients with bicuspid aortic stenosis.

作者信息

Jia Yuheng, Khokhar Arif A, Pilgrim Thomas, Costa Giuliano, Mylotte Darren, Sammartino Sofia, Tomii Daijiro, Fosbøl Emil, Tamburino Corrado, Kofoed Klaus Fuglsang, Barbanti Marco, Windecker Stephan, Chen Mao, De Backer Ole

机构信息

The Heart Center, Rigshospitalet, Copenhagen, Denmark.

Department of Cardiology, West China Hospital, Chengdu, China.

出版信息

Clin Res Cardiol. 2025 Mar;114(3):375-384. doi: 10.1007/s00392-024-02545-9. Epub 2024 Sep 19.


DOI:10.1007/s00392-024-02545-9
PMID:39297943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11913895/
Abstract

BACKGROUND: Patients undergoing transcatheter aortic valve implantation (TAVI) for bicuspid aortic stenosis (AS) frequently present with ascending aortic (AAo) dilatation which is left untreated. The objective of this study was to study the natural progression and underlying mechanisms of AAo dilatation after TAVI for bicuspid AS. METHODS: Patients with a native bicuspid AS and a baseline AAo maximum diameter > 40 mm treated by TAVI and in whom post-TAVI computed tomography (CT) scans beyond 1 year were available were included. AAo dilatation was deemed to be either continuous (≥ 2 mm increase) or stable (< 2 mm increase or decrease). Uni- and multivariate logistic regression analysis was utilized in order to identify factors associated with continuous AAo dilatation post-TAVI. RESULTS: A total of 61 patients with a mean AAo maximum diameter of 45.6 ± 3.9 mm at baseline were evaluated. At a median follow-up of 2.9 years, AAo dimensions remained stable in 85% of patients. Continuous AAo dilatation was observed in 15% of patients at a rate of 1.4 mm/year. Factors associated with continuous AAo dilatation were raphe length/annulus mean diameter ratio (OR 4.09, 95% CI [1.40-16.7], p = 0.022), TAV eccentricity at the leaflet outflow level (OR 2.11, 95%CI [1.12-4.53], p = 0.031) and maximum transprosthetic gradient (OR 1.30, 95%CI [0.99-1.73], p = 0.058). CONCLUSIONS: Ascending aortic dilatation in patients undergoing TAVI for bicuspid AS remains stable in the majority of patients. Factors influencing TAV stent frame geometry and function were identified to be associated with continuous AAo dilatation after TAVI; this should be confirmed in future larger cohort studies.

摘要

背景:接受经导管主动脉瓣植入术(TAVI)治疗二叶式主动脉瓣狭窄(AS)的患者常伴有升主动脉(AAo)扩张,但未得到治疗。本研究的目的是探讨TAVI治疗二叶式AS后AAo扩张的自然进展及潜在机制。 方法:纳入接受TAVI治疗的原发性二叶式AS患者,基线时AAo最大直径>40 mm,且有术后1年以上的计算机断层扫描(CT)图像。AAo扩张被定义为持续扩张(增加≥2 mm)或稳定(增加或减少<2 mm)。采用单因素和多因素逻辑回归分析,以确定与TAVI术后AAo持续扩张相关的因素。 结果:共评估61例患者,基线时AAo平均最大直径为45.6±3.9 mm。中位随访2.9年时,85%的患者AAo尺寸保持稳定。15%的患者出现AAo持续扩张,扩张速率为1.4 mm/年。与AAo持续扩张相关的因素包括嵴长度/瓣环平均直径比(OR 4.09,95%CI [1.40-16.7],p = 0.022)、瓣叶流出道水平的TAV偏心度(OR 2.11,95%CI [1.12-4.53],p = 0.031)和最大跨瓣压差(OR 1.30,95%CI [0.99-1.73],p = 0.058)。 结论:接受TAVI治疗二叶式AS的患者中,大多数患者的升主动脉扩张保持稳定。影响TAV支架框架几何形状和功能的因素被确定与TAVI术后AAo持续扩张相关;这一点应在未来更大规模的队列研究中得到证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/994439454673/392_2024_2545_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/aa0970a31595/392_2024_2545_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/af767494bf3b/392_2024_2545_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/994439454673/392_2024_2545_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/aa0970a31595/392_2024_2545_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/af767494bf3b/392_2024_2545_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a64/11913895/994439454673/392_2024_2545_Fig2_HTML.jpg

相似文献

[1]
Incidence and predictors of continued ascending aortic dilatation after TAVI in patients with bicuspid aortic stenosis.

Clin Res Cardiol. 2025-3

[2]
Computed tomography characteristics of the aortic valve and the geometry of SAPIEN 3 transcatheter heart valve in patients with bicuspid aortic valve disease.

Eur Heart J Cardiovasc Imaging. 2018-12-1

[3]
Long-term Fate of Dilated Ascending Aorta after Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Disease.

Am J Cardiol. 2020-5-26

[4]
The analysis of ascending aortic dilatation in patients with a bicuspid aortic valve using the ratio of the diameters of the ascending and descending aorta.

J Cardiothorac Surg. 2014-6-19

[5]
Effect of Aortic Valve Replacement on Aortic Root Dilatation Rate in Patients With Bicuspid and Tricuspid Aortic Valves.

Ann Thorac Surg. 2016-12

[6]
Mid-term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry.

Catheter Cardiovasc Interv. 2023-11

[7]
Patterns of ascending aortic dilatation and predictors of surgical replacement of the aorta: A comparison of bicuspid and tricuspid aortic valve patients over eight years of follow-up.

J Mol Cell Cardiol. 2019-7-23

[8]
Aortic flow patterns and wall shear stress maps by 4D-flow cardiovascular magnetic resonance in the assessment of aortic dilatation in bicuspid aortic valve disease.

J Cardiovasc Magn Reson. 2018-4-26

[9]
The aortic root does not dilate over time after replacement of the aortic valve and ascending aorta in patients with bicuspid or tricuspid aortic valves.

J Thorac Cardiovasc Surg. 2018-3-13

[10]
Transcatheter aortic valve implantation in bicuspid anatomy: procedural results with two different types of valves.

Minerva Cardioangiol. 2018-4

本文引用的文献

[1]
Incidence, progression, and outcomes of heart failure with improved ejection fraction: The added value of longitudinally assessed ejection fraction.

Int J Cardiol. 2025-2-1

[2]
Immune thrombocytopenia increases the risk of thrombosis: A two-sample Mendelian randomization study.

Int J Cardiol. 2024-11-1

[3]
Outcomes for patients undergoing transcatheter aortic valve replacement with ascending aorta dilation.

Int J Cardiol. 2024-6-15

[4]
EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ.

Eur J Cardiothorac Surg. 2024-2-1

[5]
Prognostic Impact of Ascending Aortic Dilatation in Bicuspid TAVR Patients.

JACC Cardiovasc Interv. 2023-12-25

[6]
Bicuspid aortic valve: long-term morbidity and mortality.

Eur Heart J. 2023-11-14

[7]
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.

Eur Heart J. 2022-10-7

[8]
Deformation of Transcatheter Aortic Valve Prostheses: Implications for Hypoattenuating Leaflet Thickening and Clinical Outcomes.

Circulation. 2022-8-9

[9]
Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?

Eur Heart J. 2022-8-1

[10]
2021 ESC/EACTS Guidelines for the management of valvular heart disease.

Eur Heart J. 2022-2-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索